Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 10/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | FPR2 | P25090 | 4/20 | 0.57 |
| ▸ | FPR1 | P21462 | 2/20 | 0.57 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16198171 | 0.85 | ENPP1 (0.53) | ENPP1MAPTFPR2FPR1PRMT5 | |
| SCHEMBL16208374 | 0.78 | MAPT (0.84) | MAPTFPR2FPR1PRMT5LMNA | |
| SCHEMBL16208421 | 0.78 | FPR2 (0.69) | ENPP1MAPTFPR2FPR1LDHA | |
| SCHEMBL17538636 | 0.78 | MAPT (0.75) | ENPP1MAPTFPR2FPR1PRMT5 | |
| SCHEMBL16208363 | 0.77 | MAPT (0.70) | ENPP1MAPTFPR2FPR1PRMT5 | |
| SCHEMBL20679568 | 0.75 | ENPP1 (0.74) | ENPP1MAPTFPR2 | |
| SCHEMBL30675581 | 0.75 | ENPP1 (0.74) | ENPP1MAPTFPR2 | |
| SCHEMBL12487210 | 0.75 | MPO (0.78) | MAPTLMNAPOLB | |
| SCHEMBL17531756 | 0.75 | MPO (0.73) | ENPP1MAPTFPR2FPR1LMNA | |
| SCHEMBL17538661 | 0.75 | ENPP1 (0.70) | ENPP1MAPTFPR2FPR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | CFTR, SLC11A2, MRPS18A | ENPP1 964/4885MAPT 4629/4885FPR2 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.